Sana Biotechnology, Inc. Operating Cash Flow
Sana Biotechnology, Inc. (SANA) reported Operating Cash Flow of -$70.17 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-10
- Sana Biotechnology, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$32.79M.
- Sana Biotechnology, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$37.38M.
- Sana Biotechnology, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$32.64M.
- Sana Biotechnology, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$29.43M.
- Sana Biotechnology, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$143.83M.
- Sana Biotechnology, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$223.15M.
- Sana Biotechnology, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$253.58M.
- Sana Biotechnology, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$290.05M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$32.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$70.17M 10-Q · filed 2026-08-10 | -$102.81M derived: sum of 3 quarters · filed 2026-08-10 | -$132.24M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$37.38M 10-Q · filed 2026-05-11 | -$70.02M derived: sum of 2 quarters · filed 2026-05-11 | -$99.45M derived: sum of 3 quarters · filed 2026-05-11 | -$132.55M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$32.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$62.07M derived: sum of 2 quarters · filed 2026-03-03 | -$95.17M derived: sum of 3 quarters · filed 2026-08-10 | -$143.83M 10-K · filed 2026-03-03 |
| 2025-09-30 | -$29.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$62.53M derived: sum of 2 quarters · filed 2026-08-10 | -$111.19M 10-Q · filed 2025-11-06 | -$158.35M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$33.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$81.76M 10-Q · filed 2026-08-10 | -$128.92M derived: sum of 3 quarters · filed 2026-08-10 | -$180.74M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$48.66M 10-Q · filed 2026-05-11 | -$95.82M derived: sum of 2 quarters · filed 2026-05-11 | -$147.64M derived: sum of 3 quarters · filed 2026-05-11 | -$206.18M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$47.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$98.98M derived: sum of 2 quarters · filed 2026-03-03 | -$157.52M derived: sum of 3 quarters · filed 2026-03-03 | -$223.15M 10-K · filed 2026-03-03 |
| 2024-09-30 | -$51.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$110.36M derived: sum of 2 quarters · filed 2025-11-06 | -$175.99M 10-Q · filed 2025-11-06 | -$227.95M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-06-30 | -$58.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$124.17M 10-Q · filed 2025-08-11 | -$176.13M derived: sum of 3 quarters · filed 2026-03-03 | -$239.68M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-03-31 | -$65.63M 10-Q · filed 2025-05-08 | -$117.59M derived: sum of 2 quarters · filed 2026-03-03 | -$181.14M derived: sum of 3 quarters · filed 2026-03-03 | -$239.94M derived: sum of 4 quarters · filed 2026-03-03 |
| 2023-12-31 | -$51.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$115.51M derived: sum of 2 quarters · filed 2026-03-03 | -$174.31M derived: sum of 3 quarters · filed 2026-03-03 | -$253.58M 10-K · filed 2026-03-03 |
| 2023-09-30 | -$63.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | -$122.35M derived: sum of 2 quarters · filed 2024-11-08 | -$201.62M 10-Q · filed 2024-11-08 | -$277.69M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-06-30 | -$58.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$138.07M 10-Q · filed 2024-08-08 | -$214.14M derived: sum of 3 quarters · filed 2025-03-17 | -$278.94M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-03-31 | -$79.27M 10-Q · filed 2024-05-08 | -$155.34M derived: sum of 2 quarters · filed 2025-03-17 | -$220.13M derived: sum of 3 quarters · filed 2025-03-17 | -$291.61M derived: sum of 4 quarters · filed 2025-03-17 |
| 2022-12-31 | -$76.07M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | -$140.86M derived: sum of 2 quarters · filed 2025-03-17 | -$212.34M derived: sum of 3 quarters · filed 2025-03-17 | -$290.05M 10-K · filed 2025-03-17 |
| 2022-09-30 | -$64.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$136.27M derived: sum of 2 quarters · filed 2023-11-08 | -$213.98M 10-Q · filed 2023-11-08 | -$324.08M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | -$71.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$149.19M 10-Q · filed 2023-08-03 | -$259.29M derived: sum of 3 quarters · filed 2024-02-29 | -$309.77M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | -$77.71M 10-Q · filed 2023-05-08 | -$187.81M derived: sum of 2 quarters · filed 2024-02-29 | -$238.29M derived: sum of 3 quarters · filed 2024-02-29 | -$278.85M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | -$110.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$160.59M derived: sum of 2 quarters · filed 2024-02-29 | -$201.14M derived: sum of 3 quarters · filed 2024-02-29 | -$251.05M 10-K · filed 2024-02-29 |
| 2021-09-30 | -$50.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | -$91.04M derived: sum of 2 quarters · filed 2022-11-02 | -$140.96M 10-Q · filed 2022-11-02 | -$178.51M derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-06-30 | -$40.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$90.47M 10-Q · filed 2022-08-04 | -$128.03M derived: sum of 3 quarters · filed 2023-03-16 | -$165.54M derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-03-31 | -$49.91M 10-Q · filed 2022-05-10 | -$87.47M derived: sum of 2 quarters · filed 2023-03-16 | -$124.98M derived: sum of 3 quarters · filed 2023-03-16 | -$158.35M derived: sum of 4 quarters · filed 2023-03-16 |
| 2020-12-31 | -$37.56M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$75.07M derived: sum of 2 quarters · filed 2023-03-16 | -$108.44M derived: sum of 3 quarters · filed 2023-03-16 | -$137.98M 10-K · filed 2023-03-16 |
| 2020-09-30 | -$37.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | -$70.88M derived: sum of 2 quarters · filed 2021-11-08 | -$100.42M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | -$33.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | -$62.91M 10-Q · filed 2021-08-04 | ||
| 2020-03-31 | -$29.55M 10-Q · filed 2021-05-05 | |||
| 2019-12-31 | -$85.52M 10-K · filed 2022-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |